Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents †: Profile report

Drugs in R and D

Volumn 12, Issue 3, 2012, Pages 171-173

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Profile Reports; Adolescents; Attention deficit hyperactivity disorder; Methylphenidate; Transdermal

Indexed keywords

DOPAMINE; METHYLPHENIDATE; NORADRENALIN;

ADHD RATING SCALE IV; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; DECREASED APPETITE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; INSOMNIA; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL PATCH; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE-BLIND METHOD; HUMANS; METHYLPHENIDATE; TRANSDERMAL PATCH;

EID: 84865842588     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11207490-000000000-00000     Document Type: Article

References (9)

1. Keating GM. Methylphenidate transdermal system in attention- deficit hyperactivity disorder in adolescents. CNS Drugs 2011; 25 (4): 333-42
2. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007 Jul; 46 (7): 894-921
3. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005 Jun 1; 57 (11): 1215-20
4. Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996 Mar; 35 (3): 343-51
5. Noven Pharmaceuticals, Inc.Daytrana-(methylphenidate transdermal system): US prescribing information [online]. Available from URL: http://www.daytrana. com/downloads/no venPI.pdf [Accessed 2010 Nov 29]
6. Wilens TE, Boellner SW, Ló pez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008 Jun; 47 (6): 700-8
7. Anderson VR, Scott LJ. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children. Drugs 2006; 66 (8): 1117-26
8. Findling RL, Turnbow J, Burnside J, et al. A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr 2010 Jul; 15 (7): 419-30
9. Findling RL, Katic A, Rubin R, et al. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2010 Oct; 20 (5): 365-75